# P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

> **NCT01591421** · PHASE1,PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** BKM120
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT01591421
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-06
- **Primary completion:** 2015-09-30
- **Final completion:** 2019-11-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591421, "P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01591421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*